CoChat

Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

Krystal, John H., Mathew, Sanjay J., DʼSouza, D. Cyril, Garakani, Amir, Gunduz-Bruce, Handan, Charney, Dennis S. · 2010 · CNS Drugs

The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.

Abstract

Drugs acting at metabotropic glutamate receptors (mGluRs) are among the most promising agents under development for the treatment of psychiatric disorders. The research in this area is at a relatively early stage, as there are no drugs acting at mGluRs that have been approved for the treatment of any psychiatric disorder. However, in the areas of schizophrenia, anxiety disorders and mood disorders, research conducted in animal models appears to translate well into efficacy in human laboratory-based models of psychopathology and in preliminary clinical trials. Further, the genes coding for mGluRs are implicated in the risk for a growing number of psychiatric disorders. This review highlights the best studied mGluR strategies for psychiatry, based on human molecular genetics, studies in animal models and preliminary clinical trials. It describes the potential value of mGluR2 and mGluR5 agonists and positive allosteric modulators for the treatment of schizophrenia. It also reviews evidence that group II mGluR agonists and positive allosteric modulators as well as group I mGluR antagonists might also treat anxiety disorders and some forms of depression, while mGluR2 and group I mGluR antagonists (particularly mGluR5 antagonists) might have antidepressant properties. This review also links growing insights into the role of glutamate in the pathophysiology of these disorders to hypothesized mGluR-related treatment mechanisms.

Overview

Integrity signals

Registry

Crossref · 10.2165/11533230-000000000-00000

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 222 references

Research works printed but not linked: 16

  1. Chambers, 1999, Semin Clin Neuropsychiatry, 4, 274
  2. Sanacora, 2008, Nature Rev: Drug Discov, 7, 426
  3. Pietraszek, 2004, J Physiol Pharmacol, 55, 587
  4. Rodriguez, 2007, Curr Opin Drug Discov Devel, 10, 715
  5. Fujii, 2003, Psychiatr Genet, 13, 71
  6. Farber, 1999, Schizophr Res, 36, 308
  7. Moghaddam, 1998, Science, 281, 1349, 10.1126/science.281.5381.1349 · DOI · Paper page
  8. Klodzinska, 2004, J Physiol Pharmacol, 55, 113
  9. Stachowicz, 2006, Pharmacol Rep, 58, 820
  10. Stachowicz, 2005, Pharmacol Rep, 57, 856
  11. Michelson, 2005, Neuropharmacology, 49, 84
  12. Mason, 2001, Biol Psychiatry, 49, 148S
  13. Krystal, 2008, Int J Neuropsychopharmacology, 11, 73
  14. Krystal, 2007, Swiss Med Wkly, 137, 215
  15. Palucha, 2002, Pol J Pharmacol, 54, 581
  16. Legutko, 2006 May-Jun, Pharmacol Rep, 58, 427

Cited by

See all 180

Metadata

Authors
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S.
Affiliations
  • Yale University (US)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Krystal, John H.
Venue
CNS Drugs
Published
2010-08
Volume
24
Issue
8
Pages
669-693
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2031258646
Cited by
180
References
221
Citations by year
2026: 3 · 2024: 11 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 8 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 12 · 2015: 10 · 2014: 20 · 2013: 14 · 2012: 38
FWCI
2.16
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5k05aa014906-03)
  • National Institute on Alcohol Abuse and Alcoholism (K05 AA 14906-01, R01AA011321, I-P50 AA-12870, P50AA012870)
  • National Institute of Mental Health (K23MH069656, P50MH068789, P50MH044866)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
metabotropic glutamate receptors, mGluR agonists, mGluR antagonists, mGluR2, mGluR5, positive allosteric modulators, schizophrenia, anxiety disorders, depression, mood disorders, glutamate, psychiatric drug development
MeSH terms
Animals, Antidepressive Agents, Anxiety Disorders, Central Nervous System Agents, Humans, Schizophrenia, Antipsychotic Agents, Anti-Anxiety Agents, Receptors, Metabotropic Glutamate, Mood Disorders, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. https://app.cochat.ai/papers/10.2165/11533230-000000000-00000
The paper
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010). Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs. https://doi.org/10.2165/11533230-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.